Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug April 23, 2018 For Women With Dense Breasts, An MRI May Be A Better... November 29, 2019 How I Navigated Being a Young Mom During Cancer: A Survivor’s... February 15, 2023 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 Load more HOT NEWS The stories behind Teenage and Young Adult Cancer Awareness Month Cómo compartir los resultados de las pruebas genéticas con la familia FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma
